Premium
Concomitant use of sorafenib with ombitasvir/paritaprevir/ritonavir and dasabuvir: Effectiveness and safety in clinical practice
Author(s) -
RevueltaHerrero J. L.,
GiménezManzorro A.,
MatillaPeña A.,
HerranzAlonso A.,
SanjurjoSáez M.
Publication year - 2018
Publication title -
journal of clinical pharmacy and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.622
H-Index - 73
eISSN - 1365-2710
pISSN - 0269-4727
DOI - 10.1111/jcpt.12727
Subject(s) - ombitasvir , dasabuvir , ritonavir , paritaprevir , sorafenib , concomitant , medicine , adverse effect , hepatocellular carcinoma , gastroenterology , hepatitis c virus , virology , viral load , ribavirin , virus , antiretroviral therapy
Summary What is known and objective No studies have evaluated the use of sorafenib with the direct‐acting antiviral ombitasvir/paritaprevir/ritonavir and dasabuvir ( OBV / PTV /r+ DSV ). Case summary Three hepatitis C virus genotype 1b‐infected patients with well‐preserved liver function were included in this prospective case series. The patients were taking sorafenib for advanced hepatocellular carcinoma and received OBV / PTV /r+ DSV for 12 weeks. One patient discontinued sorafenib while concomitant treatment due to grade 2 fatigue and muscular pain. The other two patients reported only grade 1 adverse effects. Sustained virologic response at 24 weeks was achieved, and no tumour recurrences were found. What is new and conclusion The concurrent use of OBV / PTV /r+ DSV with sorafenib was considered safe and effective.